As health officials grapple with a fast-moving outbreak of the Bundibugyo ebolavirus in the Democratic Republic | Officials are planning to study Mapp Biopharmaceutical’s MBP134 and Gilead Sciences’ remdesivir, which gained prominence during the COVID-19 pandemic, against the Bundibugyo ebolavirus.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Clinical trial set to test two drugs for fast-growing Ebola outbreak
US provides Ebola treatment for outbreak in Congo, bringing trials closer
US releases experimental Ebola drug for DR Congo outbreak trials
U.S. provides experimental Ebola treatment for outbreak in Congo, bringing trials closer
US sends experimental Ebola drug to DRC as outbreak trials expand
World Health Organization announces trial of two potential Ebola treatments | Africanews
U.S. starts vaccine effort for Ebola Bundibugyo as outbreak spreads
Trials of two Ebola treatments to start in DRC next week - WHO
A clinical trial testing two drugs against the Bundibugyo ebolavirus, which is driving a fast-moving outbreak in Central Africa,…
As governments and health authorities rush to meet the moment of a worsening Ebola outbreak in central Africa, Merck & Co. | As…
Clinical trials for treatments against Ebola Bundibugyo virus are ‘in a strong position’ to be launched quickly in the Democratic…
Clinical trials for treatments against Ebola Bundibugyo virus are ‘in a strong position’ to be launched quickly in the Democratic…
The WHO advisors also recommended evaluating combination therapy using a monoclonal antibody together with remdesivir.
Phase 1 trials could begin in July, likely in the UK and possibly Uganda, Richard Hatchett, chief executive of the Coalition for…
